What you have just written, Celtics, would be hard

What you have just written, Celtics, would be hard to dispute. The growth of revenues from compounding pharmacies (Main Avenue) has surprised practically everyone here. All the residual doubts left, after dealing with the convertible note problem, have been concentrated around the holdups affecting Rapimeds – especially in China. Those familiar with the status quo and the time taken over screening before approval in that major economic power speak with one voice in seeing the slow lane for approval as being inevitable, but, once it comes, the market opportunity will add a new dimension to what Scrips will, most likely, be able to achieve.. In any case, I see no lack of stamina and staying power around here.

Quote:

---

A few quarters of positive eps and if rapimeds enters the equation this stock will not stay at these levels imho.

---